Susquehanna International Group, LLP Neurocrine Biosciences Inc Transaction History

Susquehanna International Group, LLP

$527 Billion
Q2 2024

A detailed history of Susquehanna International Group, LLP transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Susquehanna International Group, LLP holds 39,398 shares of NBIX stock, worth $4.94 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

39,398

Previous 37,974 3.75%

Holding current value

$4.94 Million

Previous $5.24 Million 3.55%

% of portfolio

0.0%

Previous 0.0%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 15, 2024	BUY	$130.86 - $143.19 $186,344 - $203,902	1,424 Added 3.75%	39,398 $5.42 Million
Q1 2024 May 07, 2024	SELL	$130.4 - $143.74 $327,434 - $360,931	-2,511 Reduced 6.2%	37,974 $5.24 Million
Q4 2023 Feb 14, 2024	SELL	$106.07 - $132.76 $9.98 Million - $12.5 Million	-94,061 Reduced 69.91%	40,485 $5.33 Million
Q3 2023 Nov 14, 2023	BUY	$94.02 - $117.1 $3.63 Million - $4.53 Million	38,648 Added 40.3%	134,546 $15.1 Million
Q2 2023 Aug 11, 2023	BUY	$89.53 - $104.87 $4.89 Million - $5.72 Million	54,587 Added 132.14%	95,898 $9.04 Million
Q1 2023 May 16, 2023	BUY	$94.11 - $123.02 $2.66 Million - $3.48 Million	28,304 Added 217.61%	41,311 $4.18 Million
Q4 2022 Feb 14, 2023	SELL	$106.72 - $127.06 $653,233 - $777,734	-6,121 Reduced 32.0%	13,007 $1.55 Million
Q3 2022 Nov 14, 2022	BUY	$92.03 - $107.81 $1.27 Million - $1.48 Million	13,758 Added 256.2%	19,128 $2.03 Million
Q2 2022 Aug 15, 2022	SELL	$75.79 - $100.07 $4.36 Million - $5.76 Million	-57,535 Reduced 91.46%	5,370 $523,000
Q1 2022 May 16, 2022	BUY	$72.45 - $94.81 $315,882 - $413,371	4,360 Added 7.45%	62,905 $5.9 Million
Q4 2021 Feb 14, 2022	BUY	$79.65 - $106.22 $1.67 Million - $2.23 Million	21,006 Added 55.96%	58,545 $4.99 Million
Q3 2021 Nov 15, 2021	SELL	$86.18 - $99.03 $1.85 Million - $2.12 Million	-21,443 Reduced 36.36%	37,539 $3.6 Million
Q2 2021 Aug 11, 2021	BUY	$89.43 - $102.27 $4.13 Million - $4.72 Million	46,168 Added 360.29%	58,982 $5.74 Million
Q1 2021 May 17, 2021	SELL	$87.57 - $119.4 $16.2 Million - $22.1 Million	-184,880 Reduced 93.52%	12,814 $1.25 Million
Q4 2020 Feb 16, 2021	SELL	$86.91 - $108.33 $1.55 Million - $1.93 Million	-17,843 Reduced 8.28%	197,694 $18.9 Million
Q3 2020 Nov 16, 2020	BUY	$96.16 - $135.15 $5.72 Million - $8.04 Million	59,522 Added 38.15%	215,537 $20.7 Million
Q2 2020 Aug 14, 2020	SELL	$85.09 - $130.36 $5.04 Million - $7.72 Million	-59,220 Reduced 27.51%	156,015 $19 Million
Q1 2020 May 15, 2020	BUY	$75.11 - $113.76 $14.5 Million - $22 Million	193,477 Added 889.22%	215,235 $18.6 Million
Q4 2019 Feb 14, 2020	SELL	$86.8 - $118.57 $6.83 Million - $9.33 Million	-78,692 Reduced 78.34%	21,758 $2.34 Million
Q3 2019 Nov 14, 2019	SELL	$83.82 - $101.5 $807,773 - $978,155	-9,637 Reduced 8.75%	100,450 $9.05 Million
Q2 2019 Aug 16, 2019	BUY	$72.24 - $91.27 $340,611 - $430,338	4,715 Added 4.47%	110,087 $9.3 Million
Q2 2019 Aug 14, 2019	SELL	$72.24 - $91.27 $621,625 - $785,378	-8,605 Reduced 7.55%	105,372 $8.9 Million
Q1 2019 May 15, 2019	BUY	$69.31 - $91.53 $7.36 Million - $9.72 Million	106,242 Added 1373.52%	113,977 $10 Million
Q4 2018 Feb 14, 2019	BUY	$68.32 - $124.36 $16,260 - $29,597	238 Added 3.17%	7,735 $552,000
Q3 2018 Nov 14, 2018	SELL	$98.88 - $125.85 $1.5 Million - $1.91 Million	-15,149 Reduced 66.89%	7,497 $922,000
Q2 2018 Aug 14, 2018	BUY	$75.3 - $105.99 $501,046 - $705,257	6,654 Added 41.61%	22,646 $2.23 Million
Q4 2017 Feb 14, 2018	SELL	$58.53 - $77.59 $1.87 Million - $2.48 Million	-31,938 Reduced 66.63%	15,992 $1.24 Million
Q3 2017 Nov 14, 2017	BUY	$47.97 - $61.28 $2.3 Million - $2.94 Million	47,930	47,930 $2.94 Million

Others Institutions Holding NBIX

# of Institutions

629

Shares Held

94.2M

Call Options Held

692K

Put Options Held

406K

View Full List

About NEUROCRINE BIOSCIENCES INC

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $12B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

More about NBIX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.

Account

Susquehanna International Group, LLP Neurocrine Biosciences Inc Transaction History